A case report of hepatitis B virus reactivation 19 months after cessation of chemotherapy with rituximab

被引：1

作者：

Guo, Xiangjuan ^{[1
,2
]}

Ji, Tongtong ^{[1
]}

Xin, Shengliang ^{[1
]}

Xu, Jinghang ^{[1
]}

Yu, Yanyan ^{[1
]}

机构：

[1] Peking Univ First Hosp, Dept Infect Dis, Beijing, Peoples R China

[2] Handan Cent Hosp, Dept Infect Dis, Handan, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

关键词：

hepatitis B virus reactivation; lymphoma; rituximab; hepatitis B virus; CD20 monoclonal antibody; HBV REACTIVATION; LYMPHOMA; RISK; INFECTION;

D O I：

10.3389/fimmu.2022.1083862

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A 72-year-old woman presented to our hospital with elevation of serum transaminases. Her blood tests showed the hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) negative. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were given for the diffuse large B-cell lymphoma. She didn't receive anti- hepatitis B virus (HBV) drug for the isolated HBcAb positive. HBV reactivation confirmed based on the serum HBV DNA detectable until 19 months after stopping R-CHOP regimen. HBV DNA became undetectable after 4 weeks therapy with Tenofovir alafenamide fumarate (TAF). Serum transaminases went down to normal 3 months later after receiving TAF. HBV reactivation is a substantial risk for patients with isolated HBcAb positive receiving rituximab-containing chemotherapy without anti- HBV drug. Regular monitoring with a frequency of 1-3 months is the basis for timely diagnosis and treatment of HBV reactivation. Serum transaminases abnormalities may be the initial manifestation of HBV reactivation.

引用

页数：5

共 22 条

[1] Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose [J].

Candotti, Daniel ;

Assennato, Sonny Michael ;

Laperche, Syria ;

Allain, Jean-Pierre ;

Levicnik-Stezinar, Snezna .

GUT, 2019, 68 (02) :313-321

[2]

Chinese Society of Infectious Diseases Chinese Medical Association, 2019, Zhonghua Gan Zang Bing Za Zhi, V27, P938, DOI 10.3760/cma.j.issn.1007-3418.2019.12.007

[3] HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience [J].

Clerico, Michele ;

Dogliotti, Irene ;

Ghione, Paola ;

Zilioli, Vittorio Ruggero ;

Merli, Francesco ;

Botto, Barbara ;

Al Essa, Wael ;

Battaglini, Marcella ;

Grimaldi, Daniele ;

Cervi, Loretta ;

Ragaini, Simone ;

Ferrero, Simone ;

Peri, Veronica ;

De Luca, Gabriele ;

Marzano, Alfredo ;

Cavallo, Federica .

JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02)

[4] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection [J].

Lampertico P. ;

Agarwal K. ;

Berg T. ;

Buti M. ;

Janssen H.L.A. ;

Papatheodoridis G. ;

Zoulim F. ;

Tacke F. .

JOURNAL OF HEPATOLOGY, 2017, 67 (02) :370-398

[5] Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma [J].

Hara, Tasuku ;

Oka, Kohei ;

Iwai, Naoto ;

Inada, Yutaka ;

Tsuji, Toshifumi ;

Okuda, Takashi ;

Nagata, Akihiro ;

Komaki, Toshiyuki ;

Kagawa, Keizo .

INTERNAL MEDICINE, 2021, 60 (03) :417-421

[6] Chemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients With Resolved HBV Infection: A Prospective Study [J].

Hsu, Chiun ;

Tsou, Hsiao-Hui ;

Lin, Shyh-Jer ;

Wang, Ming-Chung ;

Yao, Ming ;

Hwang, Wen-Li ;

Kao, Woei-Yau ;

Chiu, Chang-Fang ;

Lin, Sheng-Fung ;

Lin, Johnson ;

Chang, Cheng-Shyong ;

Tien, Hwei-Fang ;

Liu, Tsang-Wu ;

Chen, Pei-Jer ;

Cheng, Ann-Lii .

HEPATOLOGY, 2014, 59 (06) :2092-2100

[7]

Hui CK, 2006, GASTROENTEROLOGY, V131, P59, DOI 10.1053/j.gastro.2006.04.015

[8] Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update [J].

Hwang, Jessica P. ;

Feld, Jordan J. ;

Hammond, Sarah P. ;

Wang, Su H. ;

Alston-Johnson, Devena E. ;

Cryer, Donna R. ;

Hershman, Dawn L. ;

Loehrer, Andrew P. ;

Sabichi, Anita L. ;

Symington, Banu E. ;

Terrault, Norah ;

Wong, Melisa L. ;

Somerfield, Mark R. ;

Artz, Andrew S. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) :3698-+

[9] Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis [J].

Koo, Yu Xuan ;

Tay, Matthew ;

Teh, Yii Ean ;

Teng, David ;

Tan, Daniel S. W. ;

Tan, Iain B. H. ;

Tai, David W. M. ;

Quek, Richard ;

Tao, Miriam ;

Lim, Soon Thye .

ANNALS OF HEMATOLOGY, 2011, 90 (10) :1219-1223

[10] Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy [J].

Kusumoto, Shigeru ;

Arcaini, Luca ;

Hong, Xiaonan ;

Jin, Jie ;

Kim, Won Seog ;

Kwong, Yok Lam ;

Peters, Marion G. ;

Tanaka, Yasuhito ;

Zelenetz, Andrew D. ;

Kuriki, Hiroshi ;

Fingerle-Rowson, Gunter ;

Nielsen, Tina ;

Ueda, Eisuke ;

Piper-Lepoutre, Hanna ;

Sellam, Gila ;

Tobinai, Kensei .

BLOOD, 2019, 133 (02) :137-146

← 1 2 3 →